Progyny COO sells 9,578 shares in planned trade

Progyny, Inc. Chief Operating Officer Melissa B. Cummings reported an open-market sale of Common Stock.

Rhea-AI Filing Summary

Progyny, Inc. Chief Operating Officer Melissa B. Cummings reported an open-market sale of Common Stock. On May 19, 2026, she sold 9,578 shares at $25.00 per share. After this transaction, she directly holds 73,371 shares of Progyny common stock.

The filing notes that the shares were sold pursuant to a Rule 10b5-1 trading plan that was entered into on December 19, 2025, indicating the sale was pre-arranged under a preset plan rather than a discretionary trade based on recent developments.

Insider Trade Summary 10b5-1

Net Seller: 9,578 shares

Net Sell 1 txn

Insider Cummings Melissa B

Role Chief Operating Officer

Sold 9,578 shs ($239K)

Type	Security	Shares	Price	Value
Sale	Common Stock	9,578	$25.00	$239K

Holdings After Transaction: Common Stock — 73,371 shares (Direct)

Footnotes (1)

1. F1. Shares sold pursuant to a Rule 10b5-1 trading plan entered into on December 19, 2025.

Key Figures

Shares sold: 9,578 shares Sale price: $25.00 per share Shares held after: 73,371 shares +2 more

5 metrics

Shares sold 9,578 shares Open-market sale on May 19, 2026

Sale price $25.00 per share Common Stock transaction

Shares held after 73,371 shares Direct ownership after transaction

Transaction code S Sale in open market or private transaction

Plan adoption date December 19, 2025 Rule 10b5-1 trading plan entry

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"Shares sold pursuant to a Rule 10b5-1 trading plan entered into on December 19, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Progyny (PGNY) report for Melissa B. Cummings?

Progyny reported that Chief Operating Officer Melissa B. Cummings sold 9,578 shares of Common Stock. The sale occurred on May 19, 2026, as an open-market transaction at $25.00 per share, and was executed under a pre-established Rule 10b5-1 trading plan.

At what price did the Progyny (PGNY) COO sell her shares?

Melissa B. Cummings sold her Progyny Common Stock at $25.00 per share. The Form 4 shows a single open-market sale of 9,578 shares on May 19, 2026, executed pursuant to a Rule 10b5-1 trading plan entered into in December 2025.

How many Progyny (PGNY) shares does Melissa B. Cummings hold after the sale?

Following the reported sale, Melissa B. Cummings directly holds 73,371 shares of Progyny Common Stock. This post-transaction balance is disclosed in the Form 4 and reflects her remaining direct ownership after selling 9,578 shares on May 19, 2026.

Was the Progyny (PGNY) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the shares were sold pursuant to a Rule 10b5-1 trading plan entered into on December 19, 2025. Such plans pre-schedule trades, indicating the timing of this May 19, 2026 sale was determined in advance rather than made opportunistically.

What role does Melissa B. Cummings hold at Progyny (PGNY)?

Melissa B. Cummings serves as Chief Operating Officer of Progyny, Inc. Her position is disclosed in the Form 4, which reports her open-market sale of 9,578 shares of Common Stock on May 19, 2026 and her remaining direct holdings afterward.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/21/2026 - 04:22 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cummings Melissa B

(Last) (First) (Middle)

C/O PROGYNY, INC.

1359 BROADWAY, 2ND FL

(Street)

NEW YORK NEW YORK 10018

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Progyny, Inc. [ PGNY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		S		9,578(1)	D	$25	73,371	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold pursuant to a Rule 10b5-1 trading plan entered into on December 19, 2025.

Remarks:

	/s/ Mark Livingston, Attorney-in-Fact	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)